Evidence map›Paper›PMID 40859033›Full record

ArticleThe EMBO journal2025

RABGAP1 is a sensor that facilitates the sorting and processing of amyloid precursor protein.

Jessica Eden, Jonathan G G Kaufman, Conceição Pereira, Eleanor Fox, Jerome Cattin-Ortolá, Lorena Benedetti, Bart Nieuwenhuis, David J Owen, Jennifer Lippincott-Schwartz, Sean Munro and 1 more

Abstract read
In one paragraph

Article in The EMBO journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jessica EdenCambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.
Jonathan G G KaufmanCambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.
Conceição PereiraCambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0003-0164-4169
Eleanor FoxCambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0009-0009-8717-2457
Jerome Cattin-OrtoláMRC laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK.
Lorena BenedettiJanelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, USA.ORCID http://orcid.org/0000-0003-3510-0258
Bart NieuwenhuisCambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-2065-2271
David J OwenCambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-8351-6322
Jennifer Lippincott-SchwartzJanelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, USA.
Sean MunroMRC laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK.ORCID http://orcid.org/0000-0001-6160-5773
David C GershlickCambridge Institute for Medical Research, University of Cambridge, Cambridge, UK. dg553@cam.ac.uk.ORCID http://orcid.org/0000-0002-0602-210X

Funding

Royal Society (The Royal Society) RGS/R2/202082UKRI | Biotechnology and Biological Sciences Research Council (BBSRC) BB/M011194/1UKRI | Biotechnology and Biological Sciences Research Council (BBSRC) BB/W005905/1UKRI | Medical Research Council (MRC) MR/V002694/1Wellcome TrustWellcome Trust 210481Wellcome Trust (WT) 207455/Z/17/ZWellcome Trust (WT) 227915/Z/23/Z
6 · The paper itself

Abstract

A hallmark of Alzheimer's disease (AD) is the accumulation of extracellular amyloid-β plaques in the brain. Amyloid-β is a 40-42 amino acid peptide generated by proteolytic processing of amyloid precursor protein (APP) via membrane-bound proteases. APP is a transmembrane protein, and its trafficking to sites of proteolysis represents a rate-limiting step in AD progression. Although APP processing has been well-studied, its trafficking itinerary and machinery remain incompletely understood. To address this, we performed an unbiased interaction screen for interactors of the APP cytosolic tail. We identified previously characterised APP binders as well as novel interactors, including RABGAP1. We demonstrated that RABGAP1 partially co-localises with APP and directly interacts with a YENPTY motif in the APP cytosolic tail. Depletion or overexpression of RABGAP1 caused mistrafficking and misprocessing of endogenous APP in human and rodent neurons. This effect is dependent on the GAP activity of RABGAP1, demonstrating that RABGAP1 affects the trafficking of APP by modulating RAB activity on endosomal subdomains. This novel trafficking mechanism has implications for other NPXY cargoes and presents a possible therapeutic avenue to explore.

Indexed as

Amyloid beta-Protein PrecursorGTPase-Activating ProteinsAlzheimer DiseaseAnimalsHEK293 CellsHumansMiceNeuronsProtein TransportAmyloid beta-Protein PrecursorGTPase-Activating ProteinsAlzheimer’s DiseaseAPPRABGAP1Trafficking

Identifiers

PMID40859033
PMCPMC12489035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.